Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference

Tuesday, January 6, 2009 General News J E 4
BASKING RIDGE, N.J., Jan. 6 Regado Biosciences, Inc. announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 14, 2009, at 11:30am Pacific Time (2:30pm Eastern Time). Dr. Mazzo's presentation will include a review of the Company's lead compound in development, the REG1 System, its pipeline and enterprise-level business initiatives.

About Regado Biosciences

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system is comprised of an aptamer therapeutic that can be controlled directly by its specific and matched reversal agent. This technology is being applied to acute care injectable antithrombotics, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to directly control and titrate each system's therapeutic effect providing a safe and unique approach to personalized medicine.

Regado's lead program, the REG1 System, is comprised of two parenteral agents, the first being a potent and highly selective Factor IXa inhibitor and the second being its complementary reversal agent which can be used to completely or selectively lower the anticoagulant effects. The REG1 System is currently in Phase 2 clinical testing.

SOURCE Regado Biosciences, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Why Are So Many Americans Wearing Gold Earrings on...
Schering-Plough Schedules Conference Call and Webc...